» The foundation of primum non nocere, or “first do no harm,” was built upon the ideology of Veneni dextera dextrae Tempus, or “right poison, right time,” ...
…which grants the clinician agency to, while following clinical-based evidence, use their best judgement in prescribing and monitoring chemical medications (both brand-name and generic), over-the-counter products and even contemporary-traditional remedies. The two issues of FAQ that I previously led (“Clinical Foot and Ankle Pathology” in 2010 and its 2020 companion, “Clinical Pharmacology for the Lower Extremity Professional: An Update”) focused on the aims and essential consciousness of podiatric providers when making these decisions.
In the years since, our healthcare system has grappled with many obvious challenges – some long-standing, such as the opioid crisis, short staffing and the closure of rural hospitals, and some sudden and devastating, as with COVID-19. Great promise, however, is continuously presenting itself in the form of medical discoveries, specifically in the area of biologic therapeutics.
For the lower extremity clinician, these advancements point to the words of Hippocrates: “The physician must be able to tell the antecedents, know the present, and foretell the future… to do good or to do no harm” This keystone quote is the principal motivation for this issue.
Lower extremity specialists need to be familiar with and willing to explore critical elements of biologic therapeutics, not only because they may prescribe them to treat their patients, but also because they may be part of an interdisciplinary team whose other members are prescribing them. It is imperative that clinicians understand how these biologics may affect their patients, both outside and within their scope of practice. With this in mind, this issue’s Feature Article covers essential elements of these biologic therapeutics.
Our first Audio Lecture primarily focuses on the American drug approval process by the Food and Drug Administration (FDA), and explores the history of the organization, drug approvals, drug recalls and “black box” warnings pertinent to the lower extremity scope. The second lecture, centered specifically on platelet-rich plasma, is given by Dr. Brandon Brooks, a leader among our profession and a brilliant comet within the constellation of pain management and mitigating opioid harm. The condensations and commentaries in this issue are varied, with a general focus on updated relative pharmacology, therapeutics and innovations relevant (yet controversial) to our field, presented in recently-published investigations and narratives on the evolving ideology of pharmacotherapy.
In its review of many advances and changing viewpoints in pharmacotherapeutics, my hope is that this issue will enhance the knowledge base of the practicing foot and ankle specialist, helping them in selecting appropriate therapeutic agents for their diverse patient population with confidence.
Robert G. Smith, DPM, Msc, RPh, FNAP
2023 by Data Trace Publishing Company. All rights reserved. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the United States Copyright Law without the permission of the copyright owner is unlawful. No portion(s) of the work(s) may be reproduced without written consent from Data Trace Publishing Company. Permission to reproduce copies of articles for non-commercial use may be obtained for a fee of $22 per copy from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, www.copy right.com.
The ideas and opinions expressed in Foot and Ankle Quarterly are those of the authors and do not necessarily reflect those of the Editor or the Publisher. Publication of an advertisement or other product mentioned in Foot and Ankle Quarterly should not be construed as an endorsement of the product of the manufacturer’s claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The Publisher does not assume any responsibility for any injury and/or damage to any persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device or of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other healthcare professionals, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.
Disclosure
Data Trace Publishing Company Continuing Education Mission Statement
Data Trace Publishing Company is committed to providing high-quality print and internet-based enduring continuing education programs, including lectures, feature articles, and condensations and commentaries on current clinical podiatric topics and medical risk management topics which lead to improved delivery of patient care and help reduce the potential for medical errors. These programs are provided to meet the educational needs of the podiatric medical profession and thereby enhance the quality of patient care.
Program Objectives
Foot and Ankle Quarterly (FAQ) is a unique program designed to help today’s podiatric physician manage an ever-increasing flow of information. After completing the Foot and Ankle Quarterly, Volume 34 program, the learner should be better able to: develop and refine a perspective on current treatment recommendations, updates, and advances pertinent to podiatric practice; evaluate the implications of the learned information as it pertains to the diagnosis and treatment of podiatric disorders and societal issues and barriers, and; apply current trends, standards, and best practices into learner’s own practice.
Data Trace Publishing Company Continuing Education Accreditation Statement
Data Trace Publishing Company is approved by the Council on Podiatric Medical Education (CPME) as a provider of continuing education in podiatric medicine. Data Trace Publishing Company has approved this activity for a maximum of 6 continuing education contact hours (CECHs). Physicians should claim only the contact hours commensurate with the extent of their participation in the activity.
Estimated time to complete activity: 6 hours
Date of release: February 28th, 2024 Expiration Date: February 28th, 2027 (unless further validated and extended by provider). For amended dates of activity expiration, please see FAQ Activity Effective Dates at www.datatrace.com).
Commercial Interests
No commercial interest provided financial support for this continuing education activity.
CECH Note
Participants of Volume 34, Issue 3 will receive a maximum of 6 CECHs for a correctly-completed CME Answer Form. In order to qualify for CECHs, a score of 70% or more must be achieved on the written examination material. Any participant who does not pass the first time may take the exam one additional time (within 90 days of receipt of results). One retake test may be taken for a fee of $15. You will be responsible for notifying your state of the number of contact hours you have received.
Participants are required to complete a course evaluation for use in developing future issues and to meet the unique educational needs of podiatric physicians.
FINANCIAL DISCLOSURE INFORMATION
It is the policy of Data Trace Publishing Company to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty, presenters, speakers, authors, and reviewers participating in any programs provided by Data Trace Publishing Company are expected to disclose any relevant financial relationships with CPME-defined commercial interests to the program audience. “Relevant financial relationships” are financial relationships of the individual (including those of the individual’s spouse or partner) in any amount occurring within the past 12 months that create a conflict of interest. A commercial interest is any organization manufacturing, producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on patients. The CPME mandates that the content of accredited activities be objective and independent of commercial bias. The intent of this policy is that readers may form their own judgements about the presentations, using independent review to resolve all identified conflicts of interest.
In addition to disclosing commercial relationships, faculty are advised of the following policies:
Each continuing education planner and author has submitted a Conflict of Interest Disclosure in order to identify relevant financial relationships and resolve conflicts.
Limitations on Data: Presenter will ensure, to the extent possible, meaningful disclosure of limitations on data (e.g., ongoing research, interim analyses, preliminary data, or unsupported opinion).
Discussion of Unapproved Uses: If unapproved (unlabeled) uses are discussed during the continuing education activity, the presenter will disclose when a product is not approved in the United States (and/or the nation where the activity takes place) for the use under discussion.
Data Trace Publishing Company has identified the option to disclose as follows:
The following authors have disclosed whether they or a member of their immediate family:
Will be receiving an honorarium for this activity
Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they willrefer as speaker or author:
Received monetary or other significant research support
Are or had been a paid consultant
Are or had been a full-time or part-time employee
Are or had been a paid or unpaid member of an advisory or similar board
Are or had been a member or on the Board of Trustees
Other
Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they will refer as speaker or author, BUT will not be recommending any of their products over similar competitor products
Within the past 12 months, had a financial or other significant relationship with a commercial organization that markets a product to which they willrefer as speaker or author, AND will be recommending one or more of their products over similar competitor products. Recommendation will be based on:
Exclusively on data and/or clinical experience not generated by the manufacturer or derived from manufacturer-sponsored studies
Data and/or clinical experience most of which were not generated by the manufacturer or derived from manufacturer-sponsored studies
Data and/or clinical experience, most of which were generated by the manufacturer or derived from manufacturer-sponsored studies
Exclusively on data and/or clinical experience generated by the manufacturer or derived from manufacturer or derived from manufacturer-sponsored studies
Have no conflicts to disclose
Article Authors and Lecturers
Brandon M. Brooks (1. Data Trace Publishing Co.)
Darrell L. Latva (n.)
Prathiba Patel (n.)
Deep N. Shah (n.)
Robert G. Smith (1. Data Trace Publishing Co.)
Lauren L. Schnack (n.)
Ashka Trivedi (n.)
Sai Vikas Yalla (n.)
FAQ Journal Planning Committee
Chrissy Wesolowski (n.)
Lauren Molander (n.)
Stephanie Wu, DPM, MSc (n.)
Foot and Ankle Quarterly 34-4 Contributors
Guest Editor
Robert G. Smith, DPM, MSC, RPh, FNAP President/ Founder, Studying Opioid Harm (Non-Profit-501.c3), Ormond Beach, FL; Retired Podiatrist Private Practice Shoe String Podiatry, Ormond Beach, FL; Assistant Clinical Professor, Podiatry, College Podiatric Medicine, Western University of Health Sciences, Pomona, CA; Guest Lecturer, Podiatric Pharmacology, College of Podiatric Medicine and Surgery, Des Moines University; Consultant, National Board of Podiatric Medical Examiners; Certified Pedorthist; Certified Pharmacy Regulatory Specialist, Certified Pharmacist Pain Specialist.
Contributors
Brandon M. Brooks, DPM, MPH Staff Podiatrist, Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC; Treasurer and Fellow, American College of Podiatric Medicine (ACPM); 6th Public Health Fellow, American Podiatric Medical Association (APMA); Diplomate with Certificate of Added Qualification in Podiatric Surgery, American Board of Podiatric Medicine; Fellow, American Society of Podiatric Surgeons
Darrell R. Latva, DPM, FACFAS, FACPM Associate Professor; Dr. William M. Scholl College of Podiatric Medicine. Diplomate: ABFAS and ABPM.
Pratibha Patel, DPM Assistant Professor, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University, North Chicago, IL; Fellow, American Board of Podiatric Medicine
Deep N. Shah, DPM, MBA, AACFAS Assistant Professor, Department of Podiatric Medicine and Surgery, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, North Chicago, IL; Vice Chair of Surgery, Community First Medical Center, Chicago, IL; Director-at-Large, Illinois Podiatric Medical Association
Lauren L. Schnack, DPM, MS, AACDAS, FACPM Assistant Professor, Fellowship Trained Podiatric Surgeon, Department of Podiatric Medicine and Surgery, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, North Chicago, IL
Ashka Trivedi, DPM Assistant Professor, Department of Medicine and Science, Rosalind Franklin University of Medicine and Science, North Chicago, IL
Sai Vikas Yalla, PhD Assistant Professor, Chair of Scholarship Committee, Center for Lower Extremity Ambulatory Research (CLEAR), Department of Podiatric Surgery and Applied Biomechanics, Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, North Chicago, IL
34-4 In this issue:
FEATURE ARTICLE: Biologics Pharmaceuticals: Scientific gradus deinceps Robert G. Smith, DPM, MSC, RPh, FNAP
CONDENSATIONS and COMMENTARIES
Immunotherapeutic Strategies for Treating Opioid Use Disorder and Overdose
Commentary by Robert G. Smith, DPM, MSC, RPh, FNAP
Microenvironment-Based Diabetic Foot Ulcer Nanomedicine
Commentary by Lauren L. Schnack, DPM, MS, AACFAS, FACPM
The Promising Hydrogel Candidates for Pre-Clinically Treating Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis
Commentary by Lauren L. Schnack, DPM, MS, AACFAS, FACPM
Toward Developing Immunocompetent Diabetic Foot Ulcer-on-a-Chip Models for Drug Testing
Commentary by Deep N. Shah, DPM, MBA
Regional Anesthesia in Patients on Antithrombotic Drugs: Joint ESAIC/ESRA Guidelines
Commentary by Ashka Trivedi, DPM
Drug-Induced Peripheral Neuropathy: A Narrative Review
Commentary by Darrell R. Latva, DPM, FACFAS, FACPM
Topical Gel-Based Biomaterials for the Treatment of Diabetic Foot Ulcers
Commentary by Pratibha Patel, DPM, FACPM
Meta-Analysis of Randomized Controlled Studies of Closed Incisional Negative Pressure Wound Therapy vs. Standard Wound Dressing in the Prevention of Surgical Site Infections for Patients Undergoing Surgeries for Lower Extremity Fractures
Commentary by Deep N. Shah, DPM, MBA
A Systematic Review on Smartphone Use for Activity Monitoring during Exercise Therapy in Intermittent Claudication
Commentary by Sai Vikas Yalla, PhD
Treating Severe Refractory and Augmented Restless Legs Syndrome
Commentary by Ashka Trivedi, DPM
AUDIO LECTURE 1 : The Food and Drug Administration: A Primer for the Lower Extremity Specialist
Robert G. Smith, DPM, MSC, RPh, FNAP
